RYBREVANT — JANSSEN BIOTECH, approved 2025-11-07 (BLA761210).
2,231 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.